A randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer (KOV-HIPEC-02). This is an ASCO Meeting Abstract from ...
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients ...
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and ...
Passage Bio initiated a strategic review process after regulators didn't support a single-arm trial design for its dementia drug. The Food and Drug Administration indicated a randomized controlled ...
Elemento is the director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. Sternberg is the clinical director of the Englander Institute for Precision Medicine. Khozin is ...
Adjunctive glucocorticoids may reduce mortality among patients with severe community-acquired pneumonia (CAP) in well-resourced settings. Whether these drugs are beneficial in low-resource settings ...
Alto Neuroscience, Inc. (NYSE: ANRO) shares fell first thing Tuesday. The company, a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results